Article
Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> mice
2021-06-10
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Neuroblastoma is a commonly lethal solid tumor of childhood and intensive chemoradiotherapy treatment cures ~50% of children with high-risk disease. The addition of immunotherapy using dinutuximab, a monoclonal antibody directed against the GD2 disialoganglioside expressed on neuroblasts, improves survival when incorporated into front-line therapy and shows robust activity i...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ae8d7e23-64c3-542c-ad4f-8d78a1f62efe
- DOI
- 10.1101/2021.06.09.447746
